Showing results (551-560 of 1,104) with videos related to

Sort By:
Pageof 111
Nature Communications|November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activityJacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.
Frontiers in Genetics|October 18, 2021
Corrigendum: ALG1-CDG Caused by Non-Functional Alternative Splicing Involving a Novel Pathogenic Complex AlleleCarlos Alberto González-Domínguez, Moisés O Fiesco-Roa, Samuel Gómez-Carmona, et al.
Frontiers in Genetics|September 27, 2021
ALG1-CDG Caused by Non-functional Alternative Splicing Involving a Novel Pathogenic Complex AlleleCarlos Alberto González-Domínguez, Moisés O Fiesco-Roa, Samuel Gómez-Carmona, et al.
Journal of Medicinal Chemistry|September 7, 2021
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated ResistanceM Raymond V Finlay, Peter Barton, Sue Bickerton, et al.
Journal of Inherited Metabolic Disease|July 19, 2020
International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and managementRuqaiah Altassan, Silvia Radenkovic, Andrew C Edmondson, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2019
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping PanelJason Willis, Martina I Lefterova, Alexander Artyomenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
Pageof 111